Izencitinib
Small moleculeexperimental
Clinical trial activity
9 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
6
Phase 2
1
Phase 3
2
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02657122)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase JAK1INHIBITOR
JAK1 inhibitor
- Janus Kinase (JAK)INHIBITOR
Janus Kinase (JAK) inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cc(Nc2cc3ncccc3c(N[C@@H]3C[C@H]4CC[C@@H](C3)N4CCC#N)n2)n[nH]1- Mol. weight
- 402.51 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650343 ↗
Also known as
- td-1473
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04587713 | Phase 1 | Oct 16, 2020 | Theravance |
| NCT03920254 | Phase 2/Phase 3 (Phase 3) | Jul 31, 2019 | Theravance |
| NCT03758443 | Phase 2/Phase 3 (Phase 3) | Mar 11, 2019 | Theravance |
| NCT03750565 | Phase 1 | Nov 27, 2018 | Theravance |
| NCT03635112 | Phase 2 | Aug 3, 2018 | Theravance |
| NCT03555617 | Phase 1 | Jun 13, 2018 | Theravance |
| NCT03408470 | Phase 1 | Jan 31, 2018 | Theravance |
| NCT02818686 | Phase 1 | Aug 1, 2016 | Theravance |
| NCT02657122 | Phase 1 | Dec 1, 2015 | Theravance |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Theravance | For profit | 9 | 9 | 3 | 2015 |
1 organizations
Page 1 / 1